• 1
    [No authors listed] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Polychlorinated Dibenzo-Para-Dioxins and Polychlorinated Dibenzofurans. Lyon, France, 4-11 February 1997. IARC Monogr Eval Carcinog Risks Hum. 1997; 69: 1631.
  • 2
    Giri AK. Mutagenic and genotoxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin, a review. Mutat Res. 1986; 168: 241248.
  • 3
    Hardell L. [Malignant mesenchymal tumors and exposure to phenoxy acids—a clinical observation]. Lakartidningen. 1977; 74: 27532754.
  • 4
    Institute of Medicine (IOM). Veterans and Agent Orange, Update 2000. Washington, DC: National Academy Press; 2001.
  • 5
    Crane PJ,Barnard DL,Horsley KW,Adena MA. Mortality of National Service Vietnam Veterans: The Veteran Cohort Study. A Report of the 1996 Retrospective Cohort Study of Australian Vietnam Veterans. Canberra, Australia: Department of Veterans' Affairs; 1997.
  • 6
    Australian Institute of Health and Welfare (AIHW). Morbidity of Vietnam Veterans: A Study of the Health of Australia's Vietnam Veteran Community. Vol. 3:Validation Study. Canberra, Australia: Australian Institute of Health and Welfare; 1999.
  • 7
    Giri VN,Cassidy AE,Beebe-Dimmer J, et al. Association between Agent Orange and prostate cancer: a pilot case–control study. Urology. 2004; 63: 757760; discussion 760–761.
  • 8
    Zafar MB,Terris MK. Prostate cancer detection in veterans with a history of Agent Orange exposure. J Urol. 2001; 166: 100103.
  • 9
    Pavuk M,Michalek JE,Ketchum NS. Prostate cancer in US Air Force veterans of the Vietnam War. J Expo Sci Environ Epidemiol. 2006; 16: 184190.
  • 10
    Pavuk M,Michalek JE,Schecter A,Ketchum NS,Akhtar FZ,Fox KA. Did TCDD exposure or service in Southeast Asia increase the risk of cancer in Air Force Vietnam veterans who did not spray Agent Orange? J Occup Environ Med. 2005; 47: 335342.
  • 11
    Akhtar FZ,Garabrant DH,Ketchum NS,Michalek JE. Cancer in US Air Force veterans of the Vietnam War. J Occup Environ Med. 2004; 46: 123136.
  • 12
    American Cancer Society. Cancer Facts and Figures- 2007. Atlanta, Ga: American Cancer Society; 2007.
  • 13
    Parkin DM,Whelan SL,Ferlay J,Raymond L,Young J. Cancer Incidence in Five Continents. Vol. VII.IARC Scientific Publications No. 143. Lyon, France. IARC, World Health Organization; 1997.
  • 14
    Johns LE,Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003; 91: 789794.
  • 15
    Thompson IM,Goodman PJ,Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215224.
  • 16
    Hickey K,Do KA,Green A. Smoking and prostate cancer. Epidemiol Rev. 2001; 23: 115125.
  • 17
    Moyad MA. Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. Urology. 2002; 59( 4 suppl 1): 4150.
  • 18
    Skolarus TA,Wolin KY,Grubb RL3rd. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Natl Clin Pract Urol. 2007; 4: 605614.
  • 19
    Jacobs EJ,Rodriguez C,Bain EB,Wang Y,Thun MJ,Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev. 2007; 16: 22132217.
  • 20
    Jacobs EJ,Thun MJ,Bain EB,Rodriguez C,Henley SJ,Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007; 99: 608615.
  • 21
    Gupta A,Ketchum N,Roehrborn CG,Schecter A,Aragaki CC,Michalek JE. Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Environ Health Perspect. 2006; 114: 16491654.
  • 22
    Cooperberg MR,Lubeck DP,Mehta SS,Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003; 170(6 pt 2): S21S25; discussion S26–S27.
  • 23
    Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002; 29: 173181.
  • 24
    Schecter A,Quynh HT,Papke O,Tung KC,Constable JD. Agent Orange, dioxins, and other chemicals of concern in Vietnam: update 2006. J Occup Environ Med. 2006; 48: 408413.
  • 25
    Michalek JE,Akhtar FZ,Kiel JL. Serum dioxin, insulin, fasting glucose, and sex hormone-binding globulin in veterans of Operation Ranch Hand. J Clin Endocrinol Metab. 1999; 84: 15401543.
  • 26
    Pavuk M,Schecter AJ,Akhtar FZ,Michalek JE. Serum 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) levels and thyroid function in Air Force veterans of the Vietnam War. Ann Epidemiol. 2003; 13: 335343.
  • 27
    Steenland K,Calvert G,Ketchum N,Michalek J. Dioxin and diabetes mellitus: an analysis of the combined NIOSH and Ranch Hand data. Occup Environ Med. 2001; 58: 641648.